Literature DB >> 25902332

Early Experience with the StopLoss Jones Tube.

Laura Bagdonaite1, Andrew R Pearson.   

Abstract

PURPOSE: Extrusion is the most common reason for failure after Jones tube placement. The StopLoss Jones tube (SLJT) is a new innovation in Jones tubes that incorporates a flexible silicone internal flange to resist extrusion. We present our early experience of using this new tube and associated introducer system.
METHODS: We retrospectively analysed the case notes of a single surgeon consecutive series of patients having SLJT placement from November 2011 to November 2013.
RESULTS: 29 SLJTs were placed in 25 eyes of 19 patients. Tube follow-up ranged from 1-25 months (mean 10 months) with a total of 291 tube-months. The indications for SLJT placement were: previous LJT complications (52%), failed canalicular-DCR surgery (31%), primary placement for inoperable canalicular occlusion (14%) and patent non-functioning DCR (3%). Tube length ranged from 10-16 mm. The tube introducer system was simple and effective and there were no intra-operative complications. The tube extrusion rate was 0%. Complications occurred in 5 tubes: 1 was too long, and 4 others (14%) developed conjunctival overgrowth/medial tube migration. Patient satisfaction with the tube was: 86% fully satisfied, 10% was moderately satisfied, 3% not satisfied. The overall final surgical success rate at last follow-up was 92%.
CONCLUSIONS: In this short follow-up initial study the SLJT is simple to use and has a high rate of success and patient satisfaction. The addition of the internal silicone flange appears to prevent the previously common problem of extrusion.

Entities:  

Keywords:  DCR; Jones lacrimal bypass tube; StopLoss Jones tube

Mesh:

Year:  2015        PMID: 25902332     DOI: 10.3109/01676830.2015.1014507

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  2 in total

1.  Transcaruncular laser-assisted StopLoss Lester Jones tube surgery for lacrimal canalicular obstructions.

Authors:  Yongwei Guo; Konrad R Koch; Ludwig M Heindl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-05-01       Impact factor: 3.117

2.  Can Lester Jones tubes be tolerated for decades?

Authors:  R L Scawn; D H Verity; G E Rose
Journal:  Eye (Lond)       Date:  2017-08-18       Impact factor: 3.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.